Study to characterize systemic treatment patterns of dupilumab among patients with atopic dermatitis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dupilumab (Primary) ; Azathioprine; Ciclosporin; Methotrexate; Mycophenolate
Indications Atopic dermatitis
Focus Therapeutic Use

01 Jan 2023 Results analyzing the utilization patterns of systemic immunomodulators in children with atopic dermatitis and how utilization changed after approval of dupilumab, published in the Pediatric Dermatology
17 Dec 2022 Results describing patterns of prescribing, switching and discontinuing systemic AD drugs, before and after the approval of dupilumab , published in the Pharmacoepidemiology and Drug Safety
28 Aug 2022 Results presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com